Theriva Biologics, Inc. business relationships
Companies named in Theriva Biologics, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Theriva Biologics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- 3 / 100 Top 15% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Theriva Biologics, Inc.’s annual report 2
“...m viruses (e.g. VCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.” SEC filing
“In February 2026, we entered into a license agreement (the "Rasayana License Agreement") with Rasayana Therapeutics, Inc. ("Rasayana"), pursuant to which we granted Rasayana an exclusive worldwide license with the right to grant sublicenses to research, develop, manufacture and commercialize any Pro...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.